Synjardy 5/500 mg, 5/850 mg, 5/1000 mg, 12,5/500 mg, 12,5/850 mg, 12,5/1000 mg FC tablets
PDF Leaflet Revision Date: 10 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and exercise for glycaemic control in type 2 diabetes.
Dosage (summary)
One tablet twice daily; max 25 mg empagliflozin and 2000 mg metformin.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Diuretics
- Insulin
- Lithium
Contraindications
- Type 1 Diabetes
- Severe renal failure
- Hepatic impairment
- Metabolic acidosis
Common side effects
- Hypoglycaemia
- Nausea
- Increased urination
- Genital infections
Counselling Points
- Take with meals
- Monitor for signs of lactic acidosis
- Stay hydrated
Serious warnings
- Risk of lactic acidosis
- Risk of ketoacidosis
- Volume depletion
Important Disclaimer
The Synjardy 5/500 mg, 5/850 mg, 5/1000 mg, 12,5/500 mg, 12,5/850 mg, 12,5/1000 mg FC tablets professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
